(PRWEB UK) 4 September 2014
Progeria (Huntchinson-Gilford progeria syndrome) is a very rare genetic disorder whereby symptoms resembling the aspects of aging are manifested at an early age. Children with Progeria tend to display characteristics of accelerated aging around 18-24 months. By studying this rare disease, researchers have not only been able to further their understanding of it but they have also been able to deepen their knowledge on the human aging process as well as cardiovascular disease (Source: Rare Disease Report).
SMi is proud to be hosting its 3rd annual Orphan Drugs and Rare Diseases conference on October 20th and 21st in London. This event will provide a platform for all stakeholders, inclusive of small biotechs, pharmaceutical companies, patient advocacy organisations, researchers and regulators to share perspectives and expertise to drive the field of Orphan Drugs and Rare Diseases forward.
Benefits of Attending 2014 Orphan Drugs and Rare Diseases Conference:
- Hear important insights from Daniel O’Connor, Medical Assessor, MHRA on the Early Access to Medicines Initiative and adaptive licensing
- Focus on enhancing development pathways, with the growth of the commercial pipeline for orphan drugs and rare diseases
- Assess tools for consideration to gain early market access and enhance patient recruitment
- Interactive round table discussion led by Dominic Nutt, Director of Communications, The Saatchi Cancer Initiative, M&C Saatchi on creating a culture of innovation in the field of orphan drugs and rare diseases
For more information please visit http://www.smi-online.co.uk/2014orphandrugs64.asp
If you would like to attend this conference please contact Dayo Adejuwon on +44 (0) 207 827 6070 or email email@example.com